Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Income Statement Analysis

See more : Alpha FX Group plc (AFX.L) Income Statement Analysis – Financial Results

Complete financial analysis of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Biohaven Pharmaceutical Holding Company Ltd., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

Biohaven Pharmaceutical Holding Company Ltd. (BHVN)

Industry: Biotechnology

Sector: Healthcare

Website: https://www.biohavenpharma.com

About Biohaven Pharmaceutical Holding Company Ltd.

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 for neuropsychiatric indications; and Verdiperstat, a product for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.

Metric	2023	2022	2021	2020	2019	2017
Revenue	0.00	0.00	462.51M	0.00	0.00	0.00
Cost of Revenue	3.37M	1.39M	91.66M	72.00K	0.00	0.00
Gross Profit	-3.37M	-1.39M	370.85M	-72.00K	0.00	0.00
Gross Profit Ratio	0.00%	0.00%	80.18%	0.00%	0.00%	0.00%
Research & Development	373.28M	437.07M	181.49M	98.46M	344.67M	0.00
General & Administrative	56.90M	130.86M	37.41M	16.05M	134.45M	0.00
Selling & Marketing	5.87M	0.00	0.00	0.00	0.00	0.00
SG&A	62.77M	130.86M	37.41M	16.05M	134.45M	0.00
Other Expenses	0.00	-1.91M	1.21M	0.00	0.00	0.00
Operating Expenses	436.05M	567.93M	218.90M	114.51M	479.12M	0.00
Cost & Expenses	436.05M	567.93M	218.90M	114.51M	479.12M	0.00
Interest Income	17.73M	0.00	0.00	0.00	0.00	0.00
Interest Expense	0.00	0.00	0.00	0.00	-12.71M	0.00
Depreciation & Amortization	6.91M	1.39M	1.39M	72.00K	171.86K	52.52K
EBITDA	-429.14M	-462.80M	-217.51M	-114.43M	-479.12M	0.00
EBITDA Ratio	0.00%	0.00%	-47.03%	0.00%	0.00%	0.00%
Operating Income	-436.05M	-567.93M	-218.90M	-114.51M	-479.12M	0.00
Operating Income Ratio	0.00%	0.00%	-47.33%	0.00%	0.00%	0.00%
Total Other Income/Expenses	26.50M	-1.91M	6.47M	-4.16M	-49.26M	0.00
Income Before Tax	-409.55M	-569.84M	-212.43M	-118.67M	-528.39M	0.00
Income Before Tax Ratio	0.00%	0.00%	-45.93%	0.00%	0.00%	0.00%
Income Tax Expense	-1.38M	438.00K	1.37M	-134.30K	419.00K	0.00
Net Income	-408.17M	-570.28M	-213.80M	-118.67M	-528.81M	0.00
Net Income Ratio	0.00%	0.00%	-46.23%	0.00%	0.00%	0.00%
EPS	-5.73	-12.75	-5.97	-3.31	-10.91	0.00
EPS Diluted	-5.73	-12.75	-5.97	-3.31	-10.91	0.00
Weighted Avg Shares Out	71.20M	44.74M	35.82M	35.82M	48.49M	0.00
Weighted Avg Shares Out (Dil)	71.20M	44.74M	35.82M	35.82M	48.49M	0.00

Biohaven Presents New Data with BHV-7000 Once-Daily Extended-Release Formulation Demonstrating Excellent Safety Profile and Nonclinical Data Updates at American Epilepsy Society 2024 Annual Meeting

December 6, 2024prnewswire.com

Reported expanded safety results from BHV-7000 Phase 1 multiple ascending dose studies, including the once-daily extended-release formulation being evaluated in ongoing Phase 2 and 3 clinical studies , demonstrating excellent tolerability at all doses evaluated without central nervous system (CNS)...

Biohaven's Revenue Path: SCA And Obesity Therapies

November 29, 2024seekingalpha.com

Biohaven's pipeline progression includes Troriluzole for spinocerebellar ataxia [SCA], which has shown a 50-70% reduction in disease progression over three years. BHV-2100, a non-opioid migraine treatment, targets unmet needs in a market affecting 40 million U.S. patients and 1 billion...

Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study

November 25, 2024benzinga.com

On Monday, Biohaven Ltd. BHVN updated the taldefgrobep alfa development programs in Spinal Muscular Atrophy (SMA) and obesity.

Cassava Sciences, Biohaven And Other Big Stocks Moving Lower In Monday's Pre-Market Session

November 25, 2024benzinga.com

U.S. stock futures were higher this morning, with the Dow futures gaining more than 300 points on Monday.

Biohaven's spinal muscular atrophy drug fails to meet main goal in study

November 25, 2024reuters.com

Biohaven said on Monday its experimental treatment for spinal muscular atrophy, a rare nervous system dosorder, helped improve patients' motor function in a late-stage study, but failed to achieve statistical significance compared to placebo and standard of care.

Biohaven Provides Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and Obesity

November 25, 2024prnewswire.com

In the RESILIENT SMA study, taldefgrobep alpha showed clinically meaningful improvements in motor function at all timepoints on the Motor Function Measurement-32 scale (MFM-32), but the treatment arm did not statistically separate on the primary outcome at Week 48 compared to...

Biohaven Reports Third Quarter 2024 Financial Results and Recent Business Developments

November 12, 2024prnewswire.com

Cash, cash equivalents, marketable securities and restricted cash as of October 2, 2024 totaled approximately $642 million Achieved positive topline trial results from pivotal trial with troriluzole in spinocerebellar ataxia (SCA) Troriluzole 200 mg QD dosed orally in patients with...